Novo Nordisk today announced headline
results from the final phase 3a trials for faster-acting insulin aspart,
onset^® 1 and onset^® 2. The trials investigated the efficacy and safety of
faster-acting insulin aspart compared with NovoRapid^® (insulin aspart) in a
basal-bolus regimen in people with type 1 and type 2 diabetes, respectively.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in